Barclays PLC Increases Stock Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM)

Barclays PLC boosted its stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) by 248.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,308 shares of the company’s stock after purchasing an additional 5,925 shares during the quarter. Barclays PLC’s holdings in Contineum Therapeutics were worth $158,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Perceptive Advisors LLC purchased a new stake in shares of Contineum Therapeutics during the 2nd quarter valued at about $27,589,000. FMR LLC raised its position in shares of Contineum Therapeutics by 115.4% during the 3rd quarter. FMR LLC now owns 696,927 shares of the company’s stock valued at $13,339,000 after buying an additional 373,327 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Contineum Therapeutics during the 2nd quarter valued at about $2,642,000. Driehaus Capital Management LLC purchased a new stake in shares of Contineum Therapeutics during the 2nd quarter valued at about $1,174,000. Finally, State Street Corp grew its holdings in Contineum Therapeutics by 23.7% during the 3rd quarter. State Street Corp now owns 113,566 shares of the company’s stock valued at $2,174,000 after purchasing an additional 21,760 shares during the last quarter.

Analysts Set New Price Targets

Several equities analysts recently commented on CTNM shares. Baird R W upgraded shares of Contineum Therapeutics to a “strong-buy” rating in a report on Tuesday, October 22nd. Robert W. Baird initiated coverage on shares of Contineum Therapeutics in a report on Tuesday, October 22nd. They set an “outperform” rating and a $32.00 price target on the stock. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $31.00 target price on shares of Contineum Therapeutics in a research note on Thursday, January 9th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $29.25.

Contineum Therapeutics Stock Down 0.6 %

NASDAQ CTNM opened at $11.21 on Thursday. The company has a fifty day simple moving average of $14.24 and a two-hundred day simple moving average of $16.95. Contineum Therapeutics, Inc. has a 12-month low of $11.15 and a 12-month high of $22.00.

Contineum Therapeutics (NASDAQ:CTNM) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.01. On average, research analysts expect that Contineum Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).